$レボリューション・メディスンズ(RVMD.US)$rose more than 10% Wednesday after the biotech firm reported the discovery and preclinical-to-clinical translation of its anti-tumor drug RMC-6236. RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery. Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...
Focus Financial Downgraded to Market Perform From Outperform at William Blair William Blair analyst Jeff Schmitt downgraded$Focus Financial Partners(FOCS.US)$to Market Perform from Outperform after the company reached an agreement to be acquired by Clayton, Dubilier & Rice and Stone Point Capital in an all-cash transaction valued at $53 in cash per share. Credit Suisse Upgrades Celsius Holdings to Outperform, Raises Price Target to $...
Gainers: In reaction to earnings/guidance: •$オムニコム・グループ(OMC.US)$+6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58) •$ネットフリックス(NFLX.US)$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago) •$フルトン・ファイナンシャル(FULT.US)$+4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c) •$アボットラボラトリーズ(ABT.US)$+0.6% (Ab...
レボリューション・メディスンズに関するコメント
コラムRevolution Medicines Gains 10%+ on Word of Experimental Anti-Tumor Drug
RVMD gained 10.6% to close at $36.50 on word of the experimental drug, which the company disclosed in the publication Cancer Discovery.
Revolution disclosed news of the drug on Tuesday shortly before the market closed, sending shares up 3.4% that da...
Someone just sold 25000 shares. How good they are in timing.
still right ✅️ rising
going up
Sheesh 😮💨
easy 1.00 squeeze
👀👀 breaking out
コラムUS Top Rating Updates on 2/28: DKS, CELH, FOCS, TCOM and More
William Blair analyst Jeff Schmitt downgraded $Focus Financial Partners(FOCS.US)$ to Market Perform from Outperform after the company reached an agreement to be acquired by Clayton, Dubilier & Rice and Stone Point Capital in an all-cash transaction valued at $53 in cash per share.
Credit Suisse Upgrades Celsius Holdings to Outperform, Raises Price Target to $...
コラムToday's pre-market stock movers: NFLX, NVAX, ASML, BBWI and more
In reaction to earnings/guidance:
• $オムニコム・グループ(OMC.US)$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $ネットフリックス(NFLX.US)$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $フルトン・ファイナンシャル(FULT.US)$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $アボットラボラトリーズ(ABT.US)$ +0.6% (Ab...
コラムTop upgrades and downgrades on 5/20
• $バンコ・デ・チリ(BCH.US)$ : Santander Upgrades to Outperform from Neutral - PT $25
• $コメリカ(CMA.US)$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Mirati Therapeutics(MRTX.US)$ : Guggenheim Upgrades to Buy from Neutral - PT $115
• $オリーズ・バーゲン・アウトレット・ホールディングス(OLLI.US)$ : BofA Securities Upgrades to Buy from Underperform - PT $75 (from $39)
• $トレックス(TREX.US)$ : Exane Upgrades to Neutral from Underperform - PT $75
Downgrades
• $ファーガソン(FERG.US)$ : Exane D...
まだコメントはありません